Mirum Pharmaceuticals, a fast-growing biopharmaceutical firm, is on a mission to tackle rare and orphan ailments, with LIVMARLI serving as its flagship product candidate. The investigational oral drug has been effectively developed to alleviate the symptoms of progressive familial intrahepatic cholestasis disease, Alagille syndrome, and biliary atresia disease. The California-based company's Volixibat drug, on the other hand, represents a promising treatment option for primary sclerosing cholangitis and primary biliary cholangitis in adults. Since it was founded in 2018, the company has shown remarkable dedication to achieve its goals.
Mirum Pharmaceuticals Inc's ticker is MIRM
The company's shares trade on the NASDAQ stock exchange
They are based in Foster City, California
There are 51-200 employees working at Mirum Pharmaceuticals Inc
It is mirumpharma.com
Mirum Pharmaceuticals Inc is in the Healthcare sector
Mirum Pharmaceuticals Inc is in the Biotechnology industry
The following five companies are Mirum Pharmaceuticals Inc's industry peers: